ECM Weekly (3 May 2020) - JD.com, Hangzhou Tigermed, Peijia Medical, Central China New Life

The Australia placement streak continues as we get another four equity raises this week, out of which, three were about A$1bn or more. National Australia Bank (NAB AU), Charter Hall Retail Reit (CQR AU), and Lendlease Group (LLC AU) held well above their deal price while Newcrest Mining (NCM AU) broke deal price on the first day of trading post-placement.

• National Australia Bank Placement - Risk Reward Favorable but Outlook Still Uncertain
• Charter Hall Retail REIT Placement - Large Dilution but Its Not All Bad
• Lendlease Group Placement - Big Deal, Different Narrative, but Well-Positioned for a Recovery
• Newcrest Mining Placement - Increased Exposure Will Likely Be Accretive to Earnings

Hong Kong's ECM market is also ramping up. We finally got news that JD.com Inc (ADR) (JD US) has filed confidentially for a secondary listing and, as per media reports, the deal size will be somewhere between US$2 - 4bn. Sumeet Singh shared his early thoughts on the deal in:

• JD.com HK Listing - Early Look - Getting the Ball Rolling

Other upcoming listings include Central China New Life (CCNL HK) which has already gotten approval from HKEX and will likely launch its US$300m bookbuild this coming week. Peijia Medical (1740651D CH) got approved as well. We also covered Hangzhou Tigermed Consulting (300347 CH) A/H listing. The company filed its draft prospectus last week. The team share thoughts on the listings in:

• Peijia Medical (沛嘉医疗) Pre-IPO: Deserves Valuation Premium for the TAVR Late Comer
• Central China New Life (建业新生活) Pre-IPO - Expanding Focus Beyond Property Management
• Tigermed (泰格医疗) A+H Listing: Hot Deal of the Best China Clinical-CRO Play

Beyond that, there were also two new filings. Nongfu Spring, a Chinese bottled water and beverage company, which was said to be seeking US$1bn filed its draft prospectus, and, Ocumension Therapeutics, a Shanghai Biopharma which has a portfolio of 16 ophthalmology drugs, is also looking to list.

We will be covering these IPOs soon.